ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily t
ViiV Healthcare presents positive five-year data at AIDS 2022, demonstrating the durability of fostemsavir in people living with HIV who are heavily treatment-experienced Week 240 data from the BRIGHTE-study of first-in-class fostemsavir continue to show improvement in immunologic response and favourable virologic o...